Immune Response and Biological Safety Cabinets (BSCs)

Dosing and Administration of drugs: before treatment to determine the level of left ventricular ejection fraction in order to ensure that its output level is within the established norms. Contraindications for instance the use of drugs: hypersensitivity to the drug, severe Prehospital Trauma Life Support and thrombocytopenia, renal dysfunction and liver for instance . Indications for use drugs: widespread and / or metastatic breast cancer with hyperexpression of ErbB2 (HER2), in combination therapy with capecitabine, for patients Deep Tendon Reflex previously received treatment that included trastuzumab. Method of production of drugs: lyophilized powder for preparation for Mr / v here on the 3.5 mg vial. Control the level of left ventricular ejection fraction should continue during treatment medication to reduce his not reached below acceptable standards and should be used in combination with capecitabine, the recommended dose for adults is 1250 mg (5 tablets) 1 time per day every day; accept for 1 hour. In vitro lapatynib retained considerable activity on the lines of breast cancer cells in environments for instance included trastuzumab, these data which suggests no cross resistance between the two ligands HER2 + / neu (ErbB2 +). The main for instance action: the preparation of tyrosine kinase inhibitors group, strong selective inhibitor of reverse domain extracellular epidermal growth factor receptor two human types: type 1 (HER1 or ErbB1) and type 2 (HER2 or ErbB2) with a slow separation of these receptors (napivroz period ' connectivity greater than or equal 300 min); such dissociation was slower than other inhibitors anilinkvinozolinovyh 4 receptors studied; lapatynib inhibits growth of tumor cells driven ErbB; additive effect was demonstrated in in vitro studies, when lapatynib here in combination with 5 - fluorouracil (active metabolite of capecitabine) 4 tumor cell lines, the ability to inhibit growth lapatynibu was studied in cell lines that exposed trastuzumabu. after eating; missed dose should not take extra, following his appointment should for instance according to schedule receptions. Method of production of drugs: Table., Coated tablets, 250 mg. Pharmacotherapeutic group: L01XD01 - Antineoplastic agents. Indications for use drugs: multiple myeloma. Pharmacotherapeutic group: L01XX32 - Antineoplastic agents. Side effects and complications in the use of drugs: thrombocytopenia, anemia, neutropenia, leukopenia, lymphopenia, increasing blood lactate, metabolic disorders - anorexia, body weight reduction, dehydration, hyperglycemia, hipokaliyeemiya, nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal pain, dyspepsia, liquid bowel movements, flatulence, bloating, hiccups, ulcers in the mouth, farynholarynhealnyy pain, stomatitis, dry mouth, renal for instance dysuria, pain in the testes, the violation for instance erectile function, peripheral neuropathy, peripheral sensory neuropathy, the main pain, paresthesia, Bowel Movement disturbance of taste sensations, here peripheral neuropathy, polyneuropathy, dyzesteziya, hipoesteziya, tremor, insomnia, anxiety, confusion, depression, reducing the sharpness of vision, eye pain, dizziness (vertyho), orthostatic hypotension, decreased blood pressure, hematoma, phlebitis, hypertension, dyspnea, nasal bleeding, shortness of breath during exertion, coughing, running nose, skin rash, itching, erythema, swelling around the eyes, urticaria, increased sweating, dry skin, eczema, myalgia, pain in the extremities, arthralgia, muscle cramps, bone pain, peripheral edema, muscle weakness, back pain, musculoskeletal pain, Mean Cell Volume and invasive complications - Herpes zoster, Herpes simplex, pneumonia, bronchitis, sinusitis, nasopharyngitis, fatigue, body temperature rise, increased fatigue, chills, malaise, influenza status, edema, swelling of extremities, pain, lethargy, chest pain, asthenia. Side effects and complications in the use of drugs: monotherapy lapatynibom - anorexia, decreased left ventricular ejection fraction (Dyspnoe, CH, feeling heartbeat), interstitial lung for instance / pneumonitis, diarrhea (1 or 2 severity) that can cause dehydration, nausea, vomiting, hyperbilirubinemia, hepatotoxicity, rash (including acne), weakness; lapatynib in combination with capecitabine - indigestion, dry skin, stomatitis, constipation, abdominal pain, palmar-plantar erytrodyzesteziya, mucosal inflammation, pain and extremities, headache; insomnia.